Convalescent Covid-19 sera usefulness from infection to recovery

We are in the midst of a global pandemic, similar to but with greater mortality, to what the world experienced during the coronavirus infection outbreak in 2002-2003 by Severe Acute Respiratory Syndrome (SARS) and in 2011 by Middle East Respiratory Syndrome (MERS). The new corona virus is leading to more deaths in part because it is highly contagious and believed that SAR-CoV-2 is probably being spread via asymptomatic-infected individual. What is intriguing is that since these are all coronaviruses there are similarities between COVID-19 in its genome in that it is closely related to SARS-CoV and MERS-CoV. Therefore, researchers are using accumulated clinical and experimental data on these previous viruses, to make hypothesis and even predict how the host immune system may deal with and even evade the novel corona virus. One of the recent topics that emerged in the treatment and innoculating using convalescent sera. Using convalescent sera is a form of passive antibody therapy (PAT). PAT involves administering antibodies against a given agent, in this case serum from a recovered COVID-19 patient, to a susceptible individual (i.e. an exposed healthcare worker). The exposed healthcare worker can be helped to prevent or even treat a COVID-19 infection, particularly during early exposure. This is in contrast to the other endeavor, which is to develop an active vaccination which would require the induction of an immune response which usually takes 5-10 days to develop an immune response that results in antibody production. Thus, since no active vaccine has yet been developed passive antibody administration is the only means of providing immediate immunity to susceptible persons.

So that brings the question, what does the use of convalescent sera for COVID-19 look like? Basically, when an individual becomes sick with COVID-19 and recovers, they have circulating virus-neutralizing antibodies that could be used to innoculate an exposed COVID-19 patient. Recovering patients can be screened and identified for those with high titers of neutralizing antibody. These serum containing virus-neutralizing antibodies can be administered in a prophylactic manner to prevent infection in high-risk cases. Therefore, vulnerable individuals with underlying medical conditions, health care providers, and individuals with exposure to confirmed cases of COVID-19 can get immediate antibodies to fight early viral particles before their systems are overloaded with virus. Additionally, in some cases, convalescent serum could potentially be used in individuals with early onset of clinical disease to reduce symptoms and potentially even mortality. Although there is great historical precedence in using convalescent sera to prevent disease, the efficacy of these approaches to treat an established infection is not yet known.

The main draw back to the humoral immune response is that it takes time to produce antibodies naturally. However, the production of neutralizing antibody are vital and plays a protective role by limiting infection and producing memory that respond in a later phase to prevents re-infection in the future. Based on research from other pandemic corona virus, the anticipated mechanism of action of SARS-CoV-2 by which passive antibody therapy would mediate protection is also viral neutralization. There have been some less conclusive results that other mechanisms may be possible to a lesser degree, such as antibody-dependent cellular cytotoxicity and/or phagocytosis. In addition to convalescent sera, possible sources of antibody for SARS-CoV-2 are from preparations generated in certain animal hosts, such as genetically engineered cows that produce human antibody. These animal host sources are important until more individuals contract COVID-19 and recover, at which time the number of potential donors will continue to increase.

Initially, all B cells are programmed to differentiate into plasma cells that secrete IgM. IgM antibodies are the first to respond during the primary response. However, during the T-dependent response, helper T cells secrete cytokines that induce some activated B cells to switch the original genetic program and differentiate into plasma cells that secrete other antibody classes. There are some cases, like an immune response to a T-independent antigen, that will only produce IgM and will never develop memory to that infection. The IgM will just wane over time with limited availability. These individuals would only have IgM antibody titers because they would lack the appropriate response that would have led to class switching. Conversely, B cells located in the lymph nodes most commonly class switch to IgG production. Patients responding to COVID-19 infection would have both IgM and IgG antibody titers. In addition, all memory plasma cells would secrete IgG so if patients were exposed to a secondary infection of COVID-19 they would primarily have IgG antibody titer. In fact, in a preliminary study, there was limited serology details of SARS-CoV-2 reported. One patient showed peak specific IgM at day 9 after disease onset and the switching to IgG by week 2. Some intriguing data showed that some of the patients that were confirmed COVID-19 showed some cross-reactivity with earlier SARS-CoV, but not other coronavirus. Interestingly, sera from all patients were able to neutralize SARS-CoV-2 in an in vitro plaque assay, suggesting a possible successful mounting of the humoral responses. Finally, both IgG and IgM antibodies started to increase on around day 10 after COVID-19 symptom onset, and most patients had seroconversion (class switching) within the first 3 weeks. It was also observed that the IgG and IgM antibody level against the SARS-CoV-2 internal nucleoprotein and the surface spike receptor binding domain correlated with neutralizing activity. If it was possible to screen and determine who was IgG positive we would be able to tell who has been infected and recovered and these would no longer be able to infect others.

I think the topic of using COVID-19 convalescent sera is so useful because it could be used to treat individuals with early symptoms and prevent disease in those exposed. Doctors and nurses in the front line today who have been exposed to known cases of COVID-19, some of whom have developed disease, are being quarantined. Once these healthcare workers are in quarantine they can no longer treat patients, which threatens to collapse the health care system. So far it is showing promise and it is anticipated that convalescent serum will prevent SARS-CoV-2 infection in those to whom it is administered, whether healthcare worker or among family members caring for COVID-19 patients at home.

Leave a Reply